Hainan Marine Medicine: The deadline for changing the controlling shareholder to address same-industry competition has been extended to within 2 years.

Hainan Hya Health Industry Co., Ltd. announced that it has recently received a letter from its controlling shareholder, Xinxing Jihua Group Co., Ltd. and Xinxing Jihua Pharmaceuticals Holdings Co., Ltd., regarding the extension of the commitment period for addressing the issue of competition between Xinxing Lingyun Pharmaceutical and Chemical Co., Ltd. and Tianjin Huajin Pharmaceutical Co., Ltd. The original commitment period was up to February 24, 2025, within which the controlling shareholder had pledged to resolve the competition issue within one year. However, due to historical legacy issues, profitability, audit assessment, and complexity of related procedures, it is expected that the resolution may exceed the original commitment period.